Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Tumour Diseases”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03047265
What this trial is testing

Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Carcinoma
Sun Yat-sen University 164
Testing effectiveness (Phase 2)UnknownNCT04503967
What this trial is testing

Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer

Who this might be right for
Gastric AdenocarcinomaEsophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital 48
Testing effectiveness (Phase 2)Ended earlyNCT01215136
What this trial is testing

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Who this might be right for
Transitional Cell CarcinomaBladder CarcinomaUrothelial Carcinoma
Matthew Galsky 36
Testing effectiveness (Phase 2)UnknownNCT05990231
What this trial is testing

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Who this might be right for
Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 35
Testing effectiveness (Phase 2)Study completedNCT04392102
What this trial is testing

Niraparib in Patients With Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Zai Lab (Shanghai) Co., Ltd. 15
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339839
What this trial is testing

Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

Who this might be right for
NSCLC Stage IVKRAS G12C
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 42
Large-scale testing (Phase 3)Looking for participantsNCT04436965
What this trial is testing

Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

Who this might be right for
Nasopharyngeal CarcinomaNutrition Therapy
Sun Yat-sen University 266
Large-scale testing (Phase 3)Study completedNCT01073865
What this trial is testing

Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 222
Testing effectiveness (Phase 2)Active Not RecruitingNCT04067336
What this trial is testing

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Advanced Malignant NeoplasmAcute Myeloid LeukemiaMixed Lineage Leukemia+4 more
Kura Oncology, Inc. 263
Testing effectiveness (Phase 2)Ended earlyNCT04479436
What this trial is testing

Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Daiichi Sankyo 40
Not applicableAvailableNCT04091295
What this trial is testing

BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast

Who this might be right for
Pancreatic CancerOsteosarcomaMPNST (Malignant Peripheral Nerve Sheath Tumor)+6 more
Aveni Foundation
Early research (Phase 1)Looking for participantsNCT07619339
What this trial is testing

Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 16
Testing effectiveness (Phase 2)UnknownNCT06433830
What this trial is testing

Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy

Who this might be right for
ThrombocytopeniaRadiotherapy Side Effect
Sir Run Run Shaw Hospital 50
Large-scale testing (Phase 3)Active Not RecruitingNCT06346067
What this trial is testing

Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Who this might be right for
Advanced or Metastatic NRAS-mutant Melanoma
Erasca, Inc. 78
Testing effectiveness (Phase 2)Study completedNCT00094965
What this trial is testing

Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function

Who this might be right for
Gastrointestinal Cancer
Sanofi 43
Early research (Phase 1)Study completedNCT00049400
What this trial is testing

S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction

Who this might be right for
LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
SWOG Cancer Research Network 78
Not applicableLooking for participantsNCT07374692
What this trial is testing

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

Who this might be right for
Recurrent CNS TumorsBrain CancerGliomas+3 more
National Cancer Institute (NCI) 80
Testing effectiveness (Phase 2)Study completedNCT05039177
What this trial is testing

ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Who this might be right for
Metastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma
Erasca, Inc. 101
Testing effectiveness (Phase 2)Ended earlyNCT00422877
What this trial is testing

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

Who this might be right for
Cancer of the Liver
American Regent, Inc. 13
Large-scale testing (Phase 3)Ended earlyNCT02322281
What this trial is testing

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 149
Next Page